Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment
Since the COVID-19 pandemic, cancer patients have been recognized as a group with an increased risk of complications, if they become infected with the SARS-CoV-2 virus. However, they were not included in registrational trials for COVID-19 vaccines. In the last few months data from studies investiga...
Enregistré dans:
Auteurs principaux: | Tina Zupančič, Cvetka Kuhar Grašič |
---|---|
Format: | article |
Langue: | SL |
Publié: |
Institute of Oncology Ljubljana
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/88e12c42dff240bfa773b79412dac2c8 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
What Happens to the Immune System after Vaccination or Recovery from COVID-19?
par: Bruna T. Tiyo, et autres
Publié: (2021) -
SARS-CoV-2 immunity and an overview of the COVID-19 vaccines
par: Marković Miloš
Publié: (2021) -
Insights Into the Immune Response of the Black Soldier Fly Larvae to Bacteria
par: Daniele Bruno, et autres
Publié: (2021) -
Cellular Responses in the Respiratory Tract Following Intranasal administration of Peste des petits Ruminant Vaccine in Goats
par: Ezeasor,C. V, et autres
Publié: (2013) -
REACTOGENITY OF TICK-BORNE ENCEPHALITIS VACCINE ENCEPUR ADULT AND IMMUNE RESPONSE
par: G. N. Leonova, et autres
Publié: (2014)